Introduction to Antibacterial Therapy Clinically Relevant Microbiology and Pharmacology

Download Report

Transcript Introduction to Antibacterial Therapy Clinically Relevant Microbiology and Pharmacology

Introduction to Antibacterial
Therapy
Clinically Relevant Microbiology and
Pharmacology
Edward L. Goodman, MD
August 1, 2005
Rationale

Antibiotic use (appropriate or not) leads to
microbial resistance
 Resistance results in increased morbidity,
mortality, and cost of healthcare
 Appropriate antimicrobial stewardship will
prevent or slow the emergence of resistance
among organisms (Clinical Infectious Diseases 1997; 25:584-99.)
 Antibiotics are used as “drugs of fear”
(Kunin CM Annals 1973;79:555)
Antibiotic Misuse

Surveys reveal that:
– 25 - 33% of hospitalized patients receive
antibiotics (Arch Intern Med
1997;157:1689-1694)
– 22 - 65% of antibiotic use in hospitalized
patients is inappropriate (Infection Control 1985;6:226-230)
Consequences of Misuse of
Antibiotics
 Contagious
RESISTANCE
– No equivalent downside to overuse of
endoscopy, calcium channel blockers, etc.
 Morbidity
 Mortality
 Cost
- drug toxicity
Outline

Basic Clinical Bacteriology
 Categories of Antibiotics
 Pharmacology of Antibiotics
Goodman’s Scheme for the
Major Classes of Bacterial
Pathogens

Gram Positive Cocci
 Gram Negative Rods
 Fastidious GNR
 Anaerobes
Gram Positive Cocci

Gram stain: clusters
 Catalase pos = Staph
 Coag pos = S aureus
 Coag neg = variety of
species

Chains and pairs
 Catalase neg =
streptococci
 Classify by hemolysis
 Type by specific CHO
Staphylococcus aureus

>95% produce penicillinase (beta lactamase) =
penicillin resistant
 At PHD ~50% of SA are hetero (methicillin)
resistant = MRSA
 Glycopeptide (vancomycin) intermediate (GISA)
– MIC 8-16
– Eight nationwide (one at PHD)

First VRSA reported July 5, 2002 MMWR
– Third isolate reported May 2004
– MICs 32 - >128
– No evidence of spread in families or hospital
Evolution of Drug
Resistance in S. aureus
Penicillin
Methicillin
Methicillin-resistant
Penicillin-resistant
S. aureus
S. aureus (MRSA)
[1970s]
[1950s
S. aureus
]
[1997]
Vancomycin
[1990s]
Vancomycin-
resistant
S. aureus
Vancomycin
[ 2002 ]
intermediateresistant
S. aureus
(VISA)
Vancomycin-resistant
enterococci (VRE)
MSSA vs. MRSA
Surgical Site Infections
(1994 - 2000)
Controls MSSA SSI MRSA SSI
(n=193) (n=165)
(n=121)
Death, no. (%)
4(2.1)
11(6.7)
25(20.7)
LOS after
surg., median
5
14
23
52,791
92,363
Hosp. charges, 29,455
median $
CID. 2003;36: 592-598.
Coagulase Negative Staph
Many species – S. epidermidis most
common
 Mostly methicillin resistant (65%)
 Often contaminants or colonizers – use
specific criteria to distinguish

– Major cause of overuse of vancomycin
Nosocomial Bloodstream
Isolates
All gramnegative
(21%)
Viridans
streptococci
(1%)
Other
(11%)
SCOPE Project
Coagulasenegative
staphylococci
(32%)
Candida
(8%)
Enterococci
(11%)
Staphylococci
aureus (16%)
Clin Infect Dis 1999;29:239-244
Streptococci

Beta hemolysis: Group A,B,C etc.
 Invasive – mimic staph in virulence
 S. pyogenes (Group A)
– Pharyngitis,
– Soft tissue
– Non suppurative sequellae: ARF, AGN
Beta strept - continued

S. agalactiae (Group B)
– Peripartum/Neonatal
– Diabetic foot
– Bacteremia/endocarditis/metastatic foci

Group D (non enterococcal) = S. bovis
– Associated with carcinoma of colon
Viridans Streptococci

Many species
 Streptococcus intermedius group
– Liver abscess
– Endocarditis
– GI or pharyngeal flora

Most other are mouth flora – cause IE
Enterococci







Formerly considered Group D Streptococci
now a separate genus
Bacteremia/Endocarditis
Bacteriuria
Part of mixed abdominal/pelvic infections
Intrinsically resistant to cephalosporins
No bactericidal single agent
Role in intra-abdominal infection debated
Gram Negative Rods





Fermentors
Oxidase negative
Facultative anaerobes
Enteric flora
Numerous genera

Non-fermentors
 Oxidase positive
 Pure aerobes
 Pseudomonas and
Acinetobacter
– Escherischia
– Nosocomial
– Enterobacter
– Opportunistic
– Serratia, etc
– Inherently resistant
Fastidious Gram Negative
Rods

Neisseria, Hemophilus, Moraxella, HACEK
 Require CO2 for growth
 Neisseria must be plated at bedside
– Chocolate agar with CO2
– Ligase chain reaction (like PCR) has reduced number
of cultures for N. gonorrhea


Can’t do MIC without culture
Increasing resistance to FQ
Anaerobes

Gram negative rods
– Bacteroides
– Fusobacteria

Gram positive rods
– Clostridia
– Proprionobacteria

Gram positive cocci
– Peptostreptococci and peptococci
Anaerobic Gram Negative
Rods

Produce beta lactamase
 Endogenous flora
 Part of mixed infections
 Confer foul odor
 Heterogeneous morphology
 Fastidious
Antibiotic Classification
according to Goodman

Narrow Spectrum
– Active against only one of the four classes

Broad Spectrum
– Active against more than one of the classes

Boutique
– Active against a select number within a class
Narrow Spectrum

Active mostly against only one of the
classes of bacteria
– gram positive: glycopeptides, linezolid,
daptomycin
– aerobic gram negative: aminoglycosides,
aztreonam
– anaerobes: metronidazole
Narrow Spectrum
GPC
GNR
Fastid
Anaer
++++
-----
-----
Linezolid ++++
-----
-----
Daptomy ++++
cin
AG
-----
-----
-----
only
clostridia
Only
gram pos
-----
++++
++
-----
Aztreon
-----
+++
+
-----
Metro
-----
-----
-----
++++
Vanc
Broad Spectrum

Active against more than one class
 GPC and anaerobes: clindamycin
 GPC and GNR: cephalosporins, penicillins,
T/S, newer FQ
 GPC, GNR and anaerobes: ureidopenicillins
± BLI, carbapenems
 GPC and fastidious: macrolides
Penicillins
Strep
OSSA
GNR
Fastid
Anaer
Pen
+++
--
+/--
--
+/--
Amp/
amox
Ticar
+++
--
+
+/--
+/--
++
--
++
+/--
+
Ureid
+++
--
+++
+++
++
U+BLI +++
+++
++++
+++
++++
Carba
+++
++++
++++
++++
+++
Cephalosporins
FASTID ANAER
Ceph 1
GPC non GNR
-MRSA
++++
+
--
--
Ceph 2
++
++
+
--
Cephamycin
Ceph 3
++
++
+
+++
+++
+++
+++
--
Ceph 4
+++
++++
+++
--
Pharmacodynamics

MIC=lowest concentration to inhibit growth
 MBC=the lowest concentration to kill
 Peak=highest serum level after a dose
 AUC=area under the concentration time
curve
 PAE=persistent suppression of growth
following exposure to antimicrobial
Parameters of antibacterial
efficacy

Time above MIC - beta lactams, macrolides,
clindamycin, glycopeptides
 24 hour AUC/MIC - aminoglycosides,
fluoroquinolones, azalides, tetracyclines,
glycopeptides, quinupristin/dalfopristin
 Peak/MIC - aminoglycosides,
fluoroquinolones
Time over MIC

Should exceed MIC for at least 50% of dose
interval
 Higher doses may allow adequate time over
MIC
 For most beta lactams, optimal time over
MIC can be achieved by continuous
infusion (except unstable drugs such as
imipenem, ampicillin)

Higher Serum/tissue levels
are associated with faster
killing
Aminoglycosides
– Peak/MIC ratio of >10-12 optimal
– Achieved by “Once Daily Dosing”
– PAE helps

Fluoroquinolones
– 10-12 ratio achieved for enteric GNR

PAE helps
– not achieved for Pseudomonas
– Not always for Streptococcus pneumoniae
AUC/MIC = AUIC

For Streptococcus pneumoniae, FQ should
have AUIC >= 30
 For gram negative rods where Peak/MIC
ratio of 10-12 not possible, then AUIC
should >= 125.
Antibiotic Use and Resistance

-Strong epidemiological evidence that
antibiotic use in humans and animals
associated with increasing resistance
 -Subtherapeutic dosing encourages resistant
mutants to emerge; conversely, rapid
bactericidal activity discourages
 -Hospital antibiotic control programs have
been demonstrated to reduce resistance
Total Antibiotic
Doses / Day
2.5
2
p=.001
1.5
p=.000
2000
2001
2002
1
0.5
0
Doses/Census Day
Changes in Bug/Drug
Susceptibility Patterns
30%
25%
20%
15%
10%
5%
0%
1999
2000
2001
2002
% Bug/Drug combinations having > or = 5% increase in resistance
%Bug/Drug combinations having > or = 5% decrease in resistance
Effects on Susceptibility
Other Activities of CAMP

Decrease inappropriate fluoroquinolone use
– Staff education
– Restricted reporting

Decrease inappropriate sputum and urine
cultures
– Staff education
– Laboratory disclaimer

Decrease inappropriate vancomycin levels
– Education about unnecessary peak levels
Further Activities of CAMP

Monitor surgical site infections and intervene as
necessary
– Improved timing and administration of pre-op antibiotics
– clipping not shaving
– nasal decolonization
– changing pathogens (MRSA, gram- rods)

Automated protocol-driven antibiotic prescribing
– Computerized physician order entry
Antibiotic Armageddon
“There is only a thin red line of ID
practitioners who have dedicated
themselves to rational therapy and control
of hospital infections”
Kunin CID 1997;25:240
Historic overview on treatment of
infections

2000 BC: Eat this root
 1000 AD: Say this prayer
 1800’s: Take this potion
 1940’s: Take penicillin, it is a miracle drug
 1980’s: Take this new antibiotic, it is better
 ?2005 AD: Eat this root